Privia Health Group, Inc. (PRVA) is a publicly traded company in the Healthcare — Medical - Healthcare Information Services industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Privia Health Group, Inc. functions as a national entity focused on empowering physicians throughout the United States. It partners with medical groups, health plans, and health systems, with the primary objective of optimizing physician practices, enhancing patient experiences, and appropriately compensating clinicians for care delivered both virtually and in person. To achieve this, Privia offers a comprehensive suite of services.
Is Privia Health Group, Inc. stock overvalued or undervalued in 2026?
Privia Health Group, Inc. (PRVA) trades at 101× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $7 (-70 %).
Kaplio overview: Privia Health Group, Inc.
Market cap $3B · 52 weeks $19 – $28 (22 % below the high) · P/E 101× · 2027 expected P/E 52.4× · Dividend none · Next earnings November 5, 2026 · expected EPS $0.09 · Closing price, Oct 28 · accounts published Aug 6.
- Valuation: P/E 100.7× (expensive).
- Business: ROIC 0 % (weak).
- Balance sheet: Net cash/EBITDA 8.7× (solid).
- Earnings: 2 of 8 (disappointing).
What would it be worth at its usual multiples?
At its sector median (30.4×) $7 (-70 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 3 of 7 pass
- R&D / Revenue 0.0 %, fails.
- 5y EPS growth −8.7 %, fails.
- Gross margin 9.9 %, fails.
- ROIC 0.0 %, fails.
- FCF / Net Income 707.7 %, passes.
- Net debt / EBITDA −8.7×, passes.
- P/E vs own 10y history 100.7×, passes.
Against its peers (reference peers) — Privia Health Group, Inc.: P/E 101×; EV/EBITDA —; ROIC 0.0 %; $2.8B. Waystar Holding Corp. (P/E 41.3×; EV/EBITDA 15.8×; ROIC 3.4 %; $5.5B), Doximity, Inc. (P/E 40.3×; EV/EBITDA 24.1×; ROIC 15.3 %; $6.1B), HealthEquity, Inc. (P/E 36.6×; EV/EBITDA 18.3×; ROIC 8.6 %; $8.4B).
Profitability
| Return on Equity | 0.01% |
| Return on Invested Capital | 0.00% |
| Return on Assets | 0.00% |
| Gross Margin | 7.61% |
| Operating Margin | 1.90% |
| Net Margin | 1.19% |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 1.62 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 4.78 |
Price Performance
| 1 month | +11.31% |
| 3 months | -7.73% |
| Year-to-date | -7.89% |
| 1 year | -14.69% |
| 3 years | +5.66% |
| 5 years | -15.02% |
Related companies: TEM · BTSG · HNGE · HQY · DOCS · WAY · HTFL
Explore sector: Healthcare · Medical - Healthcare Information Services
More sections of PRVA: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks